

AMENDMENTS TO THE CLAIMS

Amend the claims as follows:

1. (Currently amended): An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

Beta C'

a) amino acid sequence of SEQ ID NO:4;
b) a mature form of amino acid sequence SEQ ID NO:4;
c) a variant of a mature form of an amino acid sequence of SEQ ID NO:4; and
d) a fragment of the amino acid sequence described in a) to c), wherein said polypeptide has growth factor activity.

2. (Currently amended): The polypeptide of claim 1, wherein said polypeptide is a FCTR2 fragment of a FCTR1 polypeptide selected from the group consisting of amino acid residues 247-370 of SEQ ID NO:2, amino acid residues 247-338 of SEQ ID NO:2, and amino acid residues 339-370 of SEQ ID NO:2.

3. – 39. (Cancelled)

40. (Original): A pharmaceutical composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable carrier.

41. – 65. (Cancelled)

Beta C'

66. (New): A polypeptide dimer comprising two associated peptide fragments, wherein said peptide fragments are selected from the group consisting of amino acid residues 247-370 of SEQ ID NO:2, amino acid residues 247-338 of SEQ ID NO:2, and amino acid residues 339-370 of SEQ ID NO:2.